Lantern Pharma (NASDAQ: LTRN) CEO Panna Sharma and New Board Member Dr. Lee Schalop Discuss How AI Can Reshape CNS Oncology Drug Development
- Lantern's RADR(R) AI platform is helping identify optimal indications and pathways for precision cancer therapies.
- Dr. Schalop reflects on lessons from developing ONC201, approved for H3K27M-mutant glioma, after a 16-year journey.
- Both leaders highlight the potential for AI to accelerate regulatory reviews and clinical trial design.
- The conversation underscores how AI could reduce oncology drug timelines and costs, improving patient access to new treatments, and how STAR-001, Lantern's new CNS cancer drug, can benefit from these AI-driven insights.
In oncology, the path from molecule discovery to patient treatment often stretches over a decade and can consume hundreds of millions of dollars. Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, aims to challenge that timeline.
In a recent discussion titled "From Discovery to Clinical Trials to Patients: Key Decisions Shaping Novel CNS Oncology Medicines," Lantern CEO Panna Sharma and new board member Dr. Lee Schalop, co-founder of Oncoceutics and a key figure behind the development of ONC201 (dordaviprone), explored how data
NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN
About AINewsWire
AINewsWire ("AINW") is a specialized communications platform with a focus on the latest advancements in artificial intelligence ("AI"), including the technologies, trends and trailblazers driving innovation forward. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, AINW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today's market, AINW brings its clients unparalleled recognition and brand awareness.
AINW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from AINewsWire, text "AI" to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit www.AINewsWire.com
Please see full terms of use and disclaimers on the AINewsWire website applicable to all content provided by AINW, wherever published or re-published: https://www.AINewsWire.com/Disclaimer
AINewsWire
Los Angeles, CA
www.AINewsWire.com
310.299.1717 Office
Editor@AINewsWire.com
AINewsWire is powered by IBN
COMTEX_469498483/2801/2025-10-13T13:30:57
